BCTXL BriaCell Therapeutics Corp.
Price Chart
Executive Summary
BriaCell announced positive Phase 2 survival data for Bria-IMT in heavily pre-treated metastatic breast cancer, with median overall survival of 16.6 months for the Phase 3 formulation and 52% 12-month survival. Quality-of-life data from the ongoing Phase 3 study showed preserved global health with minimal toxicity, supporting potential home self-administration. The data will be presented at the 2026 ASCO Annual Meeting.
Actionable Insight
The 16.6-month median OS in heavily pre-treated MBC is a strong signal for a Phase 3 asset. Monitor the ASCO presentations (May 30–June 1) for additional detail and any unblinded Phase 3 data. The stock may see volatility around the conference dates.
Key Facts
- Median overall survival of 16.6 months for the Phase 3 formulation in heavily pre-treated MBC patients (median 6 prior therapies)
- 52% 12-month survival rate for the Phase 3 formulation; 44% at 12 months and 26% at 24 months overall
- No treatment-related discontinuations and no unexpected safety signals in the Phase 2 study
- Quality-of-life data from the ongoing Phase 3 study showed stable global health and key functional domains with minimal toxicity
- Biomarker analyses confirmed DTH positivity and lower baseline CTC levels as predictors of better survival
- Data to be presented at the 2026 ASCO Annual Meeting (May 29–June 2, 2026)
Financial Impact
No financial data provided; BriaCell is a clinical-stage biotech with no approved products or revenue. The positive Phase 2 survival data and QOL results could support regulatory advancement and potential partnership interest.
Risk Factors
- Phase 3 study remains blinded; unblinding at 144 mortalities could yield different results
- No revenue or near-term commercialization path; cash burn risk for a clinical-stage company
- Small Phase 2 sample size (n=32) limits statistical reliability
- Competition from approved ADCs, CPIs, and CDK4/6 inhibitors in MBC
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300068 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
18d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
May 22, 2026
22d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
May 13, 2026
4w ago
|
Press Release
| $1.08 awaiting T+20 | awaiting T+20 | — | — |
|
May 6, 2026
5w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 21, 2026
7w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 20, 2026
7w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Mar 18, 2026
12w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Mar 5, 2026
14w ago
|
Press Release
| — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access